Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2023 filed with the SEC

September 1, 2023September 1, 2023 Alterity Therapeutics

XBRL 30 June 2023 filed with the SEC

Post navigation

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Related Posts

Prana – ANA Abstract Submission NLP

October 17, 2016August 16, 2022

Alterity Therapeutics Investor Presentation

April 10, 2019August 16, 2022

2022 AGM – Meeting Recording

November 11, 2022May 23, 2023

Recent Posts

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
XBRL 30 June 2024 filed with the SEC
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065